Unknown SARS-CoV-2 pneumonia detected by PET/CT in patients with cancer

Maura Scarlattei1, Giorgio Baldari1, Mario Silva2

  • 1Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.

Tumori
|June 23, 2020
PubMed
Abstract

Insights

Positron emission tomography/computed tomography (PET/CT) can help identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia in cancer patients, even if they have no symptoms. This imaging technique aids in early detection and management during the COVID-19 pandemic.

Area of Science:

  • Nuclear medicine and oncology
  • Radiopharmaceuticals and molecular imaging
  • Infectious disease imaging

Background:

  • The COVID-19 pandemic in Italy required stringent safety protocols for cancer patient care.
  • Detecting SARS-CoV-2 infection was difficult due to asymptomatic or mild cases.

Purpose of the Study:

  • To evaluate the utility of PET/CT in identifying SARS-CoV-2 pneumonia in cancer patients.
  • To assess tracer uptake patterns in patients with concurrent cancer and COVID-19.

Main Methods:

  • Five cancer patients with unknown SARS-CoV-2 infection underwent PET/CT scans.
  • Radiopharmaceuticals used included 18F-FDG, 18F-choline (FCH), and 68Ga-PSMA.
  • Scans were performed under strict safety measures in a PET center.

Main Results:

  • All patients showed increased lung tracer uptake on PET/CT, consistent with CT findings of SARS-CoV-2 pneumonia.
  • 18F-FDG demonstrated higher mean SUVmax (5.4) compared to other tracers (mean SUVmax 3.5).

Conclusions:

  • PET/CT is a sensitive tool for hypothesizing SARS-CoV-2 pneumonia in asymptomatic cancer patients.
  • Further research is needed to correlate immune response, clinical outcomes, and PET findings.
  • The PET center maintained a low infection rate (1.6%) among patients, with no staff infections reported.